In molecular biology mir-210 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.
| mir-210 | |
|---|---|
 Conserved secondary structure of mir-210 | |
| Identifiers | |
| Symbol | mir-210 |
| Rfam | RF00679 |
| miRBase family | MIPF0000086 |
| NCBI Gene | 406992 |
| HGNC | 31587 |
| OMIM | 612982 |
| Other data | |
| RNA type | microRNA |
| Domain(s) | Eukaryota; Chordata |
| PDB structures | PDBe |
mir-210 has been strongly linked with the hypoxia pathway, and is upregulated in response to Hypoxia-inducible factors.[1] It is also overexpressed in cells affected by cardiac disease and tumours.[2] MiRNA-210 in particular, has been studied for its effects in rescuing cardiac function after myocardial infarcts via the up-regulation of angiogenesis and inhibition of cardiomyocyte apoptosis.[3]
Myocardial infarction therapy
editMyocardial infarction is cardiac tissue necrosis that results from occlusion of blood supply via coronary arteries, thereby starving cells of oxygen and nutrients (termed ischemia). Prolong ischemia will eventually kill the cells and the destruction of cardiac cells leads to tissue death, which can lead to heart failure.
Delivery of miRNA-210 to an ischemic heart improves heart function, possibly by promoting the release of angiogenic factors like interleukin-1α (IL-1α), tumor necrosis factor-α (TNF-α) and leptin, as seen in HL-1 cardiomyocytes injected with miRNA-210.[3] However, miRNA-210 also targets the Efna3 and Ptp1b genes, which are genes which endogenously regulate angiogenesis and apoptosis, respectively.[3]
Ephrin-A3 (Efna3) is a gene that is involved in the inhibition of angiogenesis. Although it is known that Efna3 inhibits the formation of new blood vessels, its specific role is still unknown.[4] MiRNA-210 suppresses Efna3 at the mRNA level, thereby allowing angiogenesis to occur in cardiac tissue post-infarct.[3]
The second target gene, protein tyrosine phosphatase-1B (Ptp1b) is involved in the induction of apoptosis. Ptp1b gene protein has been known to regulate apoptosis by regulating the phosphorylation status of apoptotic proteins such as caspase-3 and caspase-8.[5] MiRNA-210 inhibits the effects of Ptp1b protein, which suppresses its pro-apoptotic functions.[3] Therefore, suppression of these two particular genes may contribute to the improvement of cardiac tissue and function by up-regulating angiogenesis and inhibiting apoptosis of cardiomyocytes after myocardial infarct.
Biomarker
editAdrenocortical carcinoma
editMir-210 has been suggested as a useful biomarker to distinguish adrenocortical carcinoma from adrenocortical adenoma.[6]
Breast cancer
editmir-210 expression is associated with survival in breast cancer. Higher expression indicates lower probability for survival in patients with breast cancer.[7]
See also
editReferences
edit- ^ Huang X, Le QT, Giaccia AJ (May 2010). "MiR-210—micromanager of the hypoxia pathway". Trends in Molecular Medicine. 16 (5): 230–237. doi:10.1016/j.molmed.2010.03.004. PMC 3408219. PMID 20434954.
- ^ Devlin C, Greco S, Martelli F, Ivan M (February 2011). "miR-210: More than a silent player in hypoxia". IUBMB Life. 63 (2): 94–100. doi:10.1002/iub.427. PMC 4497508. PMID 21360638.
- ^ a b c d e Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC (September 2010). "MicroRNA-210 as a novel therapy for treatment of ischemic heart disease". Circulation. 122 (11 Suppl): S124–31. doi:10.1161/circulationaha.109.928424. PMC 2952325. PMID 20837903.
- ^ Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F (June 2008). "MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3". The Journal of Biological Chemistry. 283 (23): 15878–15883. doi:10.1074/jbc.m800731200. PMC 3259646. PMID 18417479.
- ^ Song H, Zhang Z, Wang L (March 2008). "Small interference RNA against PTP-1B reduces hypoxia/reoxygenation induced apoptosis of rat cardiomyocytes". Apoptosis. 13 (3): 383–393. doi:10.1007/s10495-008-0181-1. PMID 18278556. S2CID 32666751.
- ^ Szabó DR, Luconi M, Szabó PM, Tóth M, Szücs N, Horányi J, Nagy Z, Mannelli M, Patócs A, Rácz K, Igaz P (March 2014). "Analysis of circulating microRNAs in adrenocortical tumors". Laboratory Investigation; A Journal of Technical Methods and Pathology. 94 (3): 331–339. doi:10.1038/labinvest.2013.148. PMID 24336071.
- ^ Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, Győrffy B (December 2016). "miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients". Breast Cancer Research and Treatment. 160 (3): 439–446. doi:10.1007/s10549-016-4013-7. PMID 27744485. S2CID 11165696.
Further reading
edit- Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G (January 2011). "MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1)". The Journal of Biological Chemistry. 286 (1): 420–428. doi:10.1074/jbc.M110.170852. PMC 3013001. PMID 21044961.
- Li T, Cao H, Zhuang J, Wan J, Guan M, Yu B, Li X, Zhang W (January 2011). "Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans". Clinica Chimica Acta; International Journal of Clinical Chemistry. 412 (1–2): 66–70. doi:10.1016/j.cca.2010.09.029. PMID 20888330.
- Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci JE, Pouysségur J, Gounon P, Hofman P, Barbry P, Mari B (March 2011). "miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity". Cell Death and Differentiation. 18 (3): 465–478. doi:10.1038/cdd.2010.119. PMC 3131992. PMID 20885442.
- Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC (September 2010). "MicroRNA-210 as a novel therapy for treatment of ischemic heart disease". Circulation. 122 (11 Suppl): S124–31. doi:10.1161/CIRCULATIONAHA.109.928424. PMC 2952325. PMID 20837903.
- Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H (November 2010). "Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210". Antiviral Research. 88 (2): 169–175. doi:10.1016/j.antiviral.2010.08.008. PMID 20728471.
- Chen Z, Li Y, Zhang H, Huang P, Luthra R (July 2010). "Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression". Oncogene. 29 (30): 4362–4368. doi:10.1038/onc.2010.193. PMID 20498629.
- Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, Ragoussis J, Harris AL (April 2010). Gartel AL (ed.). "MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU". PLOS ONE. 5 (4): e10345. Bibcode:2010PLoSO...510345F. doi:10.1371/journal.pone.0010345. PMC 2859946. PMID 20436681.
- Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC (April 2010). "Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer". Translational Oncology. 3 (2): 109–113. doi:10.1593/tlo.09256. PMC 2847318. PMID 20360935.
- Chan SY, Loscalzo J (March 2010). "MicroRNA-210: a unique and pleiotropic hypoxamir". Cell Cycle. 9 (6): 1072–1083. doi:10.4161/cc.9.6.11006. PMC 2912143. PMID 20237418.
- Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL (May 2010). "hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer". Cancer. 116 (9): 2148–2158. doi:10.1002/cncr.25009. PMID 20187102. S2CID 29964899.
- Kushibiki T (June 2010). "Photodynamic therapy induces microRNA-210 and -296 expression in HeLa cells". Journal of Biophotonics. 3 (5–6): 368–372. doi:10.1002/jbio.200900082. PMID 19953537.
- Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R, Banfi C, Stubbs A, Calin GA, Ivan M, Capogrossi MC, Martelli F (December 2009). "An integrated approach for experimental target identification of hypoxia-induced miR-210". The Journal of Biological Chemistry. 284 (50): 35134–35143. doi:10.1074/jbc.M109.052779. PMC 2787374. PMID 19826008.
- Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J (October 2009). "MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2". Cell Metabolism. 10 (4): 273–284. doi:10.1016/j.cmet.2009.08.015. PMC 2759401. PMID 19808020.
- Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ (September 2009). "Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation". Molecular Cell. 35 (6): 856–867. doi:10.1016/j.molcel.2009.09.006. PMC 2782615. PMID 19782034.
- Mathew LK, Simon MC (September 2009). "mir-210: a sensor for hypoxic stress during tumorigenesis". Molecular Cell. 35 (6): 737–738. doi:10.1016/j.molcel.2009.09.008. PMC 2869244. PMID 19782023.
- Kim HW, Haider HK, Jiang S, Ashraf M (November 2009). "Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2". The Journal of Biological Chemistry. 284 (48): 33161–33168. doi:10.1074/jbc.M109.020925. PMC 2785158. PMID 19721136.
- Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R (August 2009). "Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression". BMB Reports. 42 (8): 493–499. doi:10.5483/BMBRep.2009.42.8.493. PMID 19712585.
- Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C (September 2009). "MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT". Cell Cycle. 8 (17): 2756–2768. doi:10.4161/cc.8.17.9387. PMID 19652553.
- Mizuno Y, Tokuzawa Y, Ninomiya Y, Yagi K, Yatsuka-Kanesaki Y, Suda T, Fukuda T, Katagiri T, Kondoh Y, Amemiya T, Tashiro H, Okazaki Y (July 2009). "miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b". FEBS Letters. 583 (13): 2263–2268. doi:10.1016/j.febslet.2009.06.006. PMID 19520079.
- Pulkkinen K, Malm T, Turunen M, Koistinaho J, Ylä-Herttuala S (July 2008). "Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210". FEBS Letters. 582 (16): 2397–2401. doi:10.1016/j.febslet.2008.05.048. PMID 18539147.
- Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F (June 2008). "MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3". The Journal of Biological Chemistry. 283 (23): 15878–15883. doi:10.1074/jbc.M800731200. PMC 3259646. PMID 18417479.
- Corn PG (February 2008). "Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence". Cancer Biology & Therapy. 7 (2): 265–267. doi:10.4161/cbt.7.2.5745. PMID 18347426.
- Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J (March 2008). "hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer". Clinical Cancer Research. 14 (5): 1340–1348. doi:10.1158/1078-0432.CCR-07-1755. PMID 18316553.
- Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L (February 2008). "miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer". Cancer Biology & Therapy. 7 (2): 255–264. doi:10.4161/cbt.7.2.5297. PMC 3233968. PMID 18059191.
External links
edit